1.17
price down icon0.85%   -0.01
after-market アフターアワーズ: 1.16 -0.01 -0.85%
loading
前日終値:
$1.18
開ける:
$1.18
24時間の取引高:
3.00M
Relative Volume:
0.91
時価総額:
$255.91M
収益:
$95,000
当期純損益:
$-327.27M
株価収益率:
-0.5519
EPS:
-2.12
ネットキャッシュフロー:
$-239.25M
1週間 パフォーマンス:
+10.38%
1か月 パフォーマンス:
-24.03%
6か月 パフォーマンス:
-52.82%
1年 パフォーマンス:
-52.44%
1日の値動き範囲:
Value
$1.10
$1.205
1週間の範囲:
Value
$1.03
$1.205
52週間の値動き範囲:
Value
$0.8621
$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
名前
Allogene Therapeutics Inc
Name
セクター
Healthcare (1170)
Name
電話
(650) 457-2700
Name
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
職員
361
Name
Twitter
@AllogeneTx
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
ALLO's Discussions on Twitter

ALLO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.17 231.85M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-14 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 再開されました Oppenheimer Outperform
2024-05-31 開始されました Piper Sandler Overweight
2024-01-05 ダウングレード Guggenheim Buy → Neutral
2024-01-05 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 開始されました Citigroup Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-21 開始されました Bernstein Mkt Perform
2023-01-24 アップグレード JP Morgan Neutral → Overweight
2023-01-06 アップグレード Robert W. Baird Neutral → Outperform
2022-12-12 ダウングレード BofA Securities Buy → Underperform
2022-08-10 ダウングレード Raymond James Outperform → Mkt Perform
2022-07-15 アップグレード Goldman Neutral → Buy
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-28 繰り返されました B. Riley Securities Buy
2021-10-20 開始されました Cowen Outperform
2021-10-08 ダウングレード Goldman Buy → Neutral
2021-10-08 ダウングレード Stifel Buy → Hold
2021-09-23 アップグレード Raymond James Mkt Perform → Outperform
2021-06-21 再開されました Jefferies Buy
2021-05-20 アップグレード Truist Hold → Buy
2021-05-14 開始されました B. Riley Securities Buy
2021-01-26 アップグレード Stifel Hold → Buy
2020-12-10 再開されました H.C. Wainwright Buy
2020-11-24 開始されました BofA Securities Buy
2020-10-23 開始されました RBC Capital Mkts Outperform
2020-06-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-29 繰り返されました H.C. Wainwright Buy
2020-05-19 アップグレード ROTH Capital Neutral → Buy
2020-05-15 アップグレード Guggenheim Neutral → Buy
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-05-14 ダウングレード SunTrust Buy → Hold
2020-04-13 開始されました SunTrust Buy
2020-03-13 開始されました H.C. Wainwright Buy
2020-03-05 開始されました Stifel Hold
2020-02-24 開始されました Berenberg Hold
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-11-04 開始されました Canaccord Genuity Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-05 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Neutral
2019-05-23 開始されました Stifel Hold
2019-03-29 開始されました Piper Jaffray Overweight
すべてを表示

Allogene Therapeutics Inc (ALLO) 最新ニュース

pulisher
Jun 01, 2025

Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025 - Nasdaq

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Breakthrough in Solid Tumors: ALLO-316 CAR T Therapy Achieves 12-Month Remission in Advanced Kidney Cancer - Stock Titan

Jun 01, 2025
pulisher
May 31, 2025

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN

May 31, 2025
pulisher
May 30, 2025

Layoff Tracker: iTeos Winds Down Operations - BioSpace

May 30, 2025
pulisher
May 29, 2025

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha

May 29, 2025
pulisher
May 28, 2025

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

May 28, 2025
pulisher
May 28, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

May 28, 2025
pulisher
May 27, 2025

Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Canada

May 27, 2025
pulisher
May 26, 2025

Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com

May 26, 2025
pulisher
May 23, 2025

Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times

May 23, 2025
pulisher
May 23, 2025

Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia

May 23, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times

May 22, 2025
pulisher
May 22, 2025

Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Breakthrough: First-Ever Allogeneic CAR T Therapy Shows Efficacy Against Solid Tumors in Kidney Cancer Trial - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st

May 22, 2025
pulisher
May 22, 2025

Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN

May 22, 2025
pulisher
May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025
pulisher
May 17, 2025

Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World

May 17, 2025
pulisher
May 16, 2025

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive

May 16, 2025
pulisher
May 15, 2025

Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus

May 15, 2025
pulisher
May 15, 2025

ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Price Target Cut by Citi Amid Timeline Delays | ALLO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Price Target Cut by Citi Amid Timel - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Price Target Lowered by Truist Securities | ALLO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Stock Drops Amid Trial Delays - GuruFocus

May 14, 2025
pulisher
May 14, 2025

RBC Capital Reiterates Outperform Rating for Allogene Therapeuti - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Downgraded by Citizens JMP | ALLO S - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Piper Sandler Lowers Price Target for Allogene Therapeutics (ALL - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics stock falls on trial delay, downgrade - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO): Price Target Lowered by Analyst | - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Piper Sandler Lowers Price Target for Allogene Therapeutics (ALLO) | ALLO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Price Target Lowered by Oppenheimer - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Price Target Lowered by Oppenheimer | ALLO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News

May 14, 2025
pulisher
May 14, 2025

Allogene (ALLO) Pioneers Future of Cell Therapy with Innovative Strategies | ALLO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Truist Lowers Price Target for Allogene Therapeutics (ALLO) Amid Trial Delays | ALLO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Target Price Adjusted by Oppenheimer | ALLO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics (ALLO) Sees Price Target Reduction by Anal - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer - TipRanks

May 14, 2025

Allogene Therapeutics Inc (ALLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):